MedPath

Study to Evaluate the Performance of a New 2-piece Ostomy Appliance vs. Flexima® 3S in Patients With Enterostomy

Not Applicable
Conditions
Enterostomy
Interventions
Device: Flexima 3S
Device: New 2-piece ostomy appliance
Registration Number
NCT03572673
Lead Sponsor
BBraun Medical SAS
Brief Summary

To compare the performance of the comparator Flexima 3S appliance to a new 2-piece appliance in patients with enterostomy.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
38
Inclusion Criteria
  • patient having a colostomy or an ileostomy for at least 1 month
  • patient currently using a flat appliance
  • patient wearing his appliance, on average, at least 5 days
  • patient with a stoma's diameter less than 65 mm
  • patient who agrees to participate in the evaluation and who have signed the inform consent
  • patient having a mental capacity to participate to the study (i.e. to understand the study and to answer to the questions)
Exclusion Criteria
  • Patient currently suffering from peristomal skin complications (bleeding or red and broken skin at the time of inclusion)
  • Patient receiving or having received, within the last month, chemotherapy or corticotherapy
  • Patient already participating in another clinical study or who have previously participated in this investigation
  • Pregnant or breast-feeding woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Flexima 3SFlexima 3SFlexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
New 2-piece ostomy applianceNew 2-piece ostomy applianceNew 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
Primary Outcome Measures
NameTimeMethod
Change from baseline in base plate wear time, on average every 5 days, up to 21 (±3) days, for each study periodOn average every 5 days, up to 21 (±3) days for each period

For each base plate, the wear time will be evaluated during 21 (±3) days

Secondary Outcome Measures
NameTimeMethod
Assessment of the condition of peristomal skinAfter base plate removal at protocol visit 1 (day 0) and visit 2 (at 21 (±3) days)

Using a standardized measuring ostomy skin tool

Assessment of use of accessoriesFrom date of randomization, on average every 5 days, after each base plate removal, up to 21 (±3) days for each study period

After each base plate removal, the patient will describe on a 8-point scale the use of accessories ("none", "protective spray", "powder", "paste", "ring", "adhesive remover", "belt", "other, to specify". No value is considered as the better outcome, it's only descriptive value.

Preference between Flexima® 3S and the new 2-piece ostomy applianceAt the end of the study, at 42 (±6) days

At the end of the study, the patient will notify the preference between Flexima® 3S and the new 2-piece appliance

Assessment of the main reason of base plate removalFrom date of randomization, on average every 5 days, after each base plate removal, up to 21 (±3) days for each study period

After each base plate removal, the patient will describe on a 7-point scale the main reason of base plate removal ("habit", "hygiene", "leakage under the base plate", "unsticking of the base plate periphery", "unsticking of the base plate, not only on the periphery", "ask for the study but the base plate could stay longer in place", "other, to specify". No value is considered as the better outcome, it's only descriptive value.

Assessment of acceptabilityAt the end of each study period (21 (±3) days), at visit 2 (21 (±3) days) and at visit 3 (42 (±6) days)

At the end of each study period (21 (±3) days), the patient will assess on a 4-point scale each parameter of acceptability ("very good", "good", "bad", "very bad". The "very good" value is considered as the better outcome.

Safety: Adverse(s) Event(s)From date of randomization until the date of first adverse event, assessed up to 42 (±6) days

Description of all adverse event related or not to the devices studied

Trial Locations

Locations (2)

Hospital Selayang

🇲🇾

Batu Caves, Malaysia

Hospital Canselor Tuanku Muhriz

🇲🇾

Kuala Lumpur, Malaysia

© Copyright 2025. All Rights Reserved by MedPath